WeVote
Log In

Bill

Bill

HB 3350

Supplemental Appropriation - DCR - Corrections - 0608

2025 Regular Session Introduced by Roger Hanshaw and 1 co-sponsor

HB 3350 shields patient access to 340B drugs by banning manufacturers and others from blocking or restricting delivery to 340B covered entities and their contract pharmacies.

Chapter 18, Acts, Regular Session, 2025
#appropriations #governor--billsrequestedby
0
WeVote Research Nonpartisan
Bill Summary · HB 3350

Summary — HB 3350 (Patient Access to Pharmacy Protection Act)

Status: Introduced Feb 18, 2025; filed Feb 25, 2025. In committee upon adjournment (as of 2025-06-28). Declares an emergency; effective immediately upon enactment.

Purpose

HB 3350 is intended to protect patient access to medications obtained through the federal 340B Drug Discount Program by preventing manufacturers and other persons from blocking, limiting, or conditioning the delivery or acquisition of 340B drugs to covered entities and their contract pharmacies. The bill emphasizes preserving access for safety-net providers and patients — particularly in rural and underserved communities.

Key definitions (selected)

  • 340B drug discount program: the federal program under 42 U.S.C. §256b.
  • 340B covered entity: an Illinois entity that qualifies under federal 340B law.
  • 340B contract pharmacy: a pharmacy (in Illinois or another U.S. state/territory) under contract with a 340B covered entity to dispense 340B drugs.

Main provisions

  • Prohibitions on interfering with access:
    • No person, including pharmaceutical manufacturers, may deny, restrict, prohibit, condition, or otherwise interfere (directly or indirectly) with a 340B covered entity’s or its authorized contract pharmacy’s acquisition or delivery of 340B drugs, unless federal law bars such receipt.
  • Limits on restrictions regarding contract pharmacies:
    • Prohibits imposition of restrictions on a covered entity’s ability to contract with or designate contract pharmacies, including restrictions on number, location, ownership, or type of pharmacy.
  • Data and inventory protections:
    • Prohibits requiring ingredient cost or pricing data related to 340B drugs unless state or federal law requires it.
    • Prohibits imposing inventory-management requirements (including audits) beyond what a state or federal agency requires.
    • Prohibits requiring submission of data/information not already required by state or federal law as a precondition to receiving 340B drugs.
  • Violations:
    • Each saleable unit of 340B drug subject to a prohibited act and each prohibited communication constitutes a separate violation.
  • Enforcement:
    • The Illinois Department of Financial and Professional Regulation is authorized to investigate and enforce the Act, including issuing subpoenas, taking sworn testimony, and examining records.
    • If a violation is suspected, the Secretary may seek enforcement actions in the name of the People of the State of Illinois through the Attorney General or a county State’s Attorney.
  • Additional provisions:
    • The bill includes preemption and severability language (details in full text).
    • Declares an emergency; effective immediately on enactment.

Who is affected

  • 340B covered entities (safety-net hospitals, community health centers, etc.) and their contract pharmacies.
  • Pharmaceutical manufacturers and other parties that control drug distribution.
  • Patients served by 340B providers, particularly in rural and underserved areas.
  • The Department of Financial and Professional Regulation and state legal offices (AG / State’s Attorneys) for enforcement.

Procedural / timeline notes

  • Multiple public hearings, work sessions, and committee actions occurred in March–April 2025 (public hearing 3/25; testimony 4/30); left pending in committee 4/30; recommended do pass with amendments and referred to Ways & Means on 4/04. As of 6/28/2025, the bill is in committee upon adjournment.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.